TCBP Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
TC Biopharm (Holdings) Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.63 |
| 52 Week High | US$138.00 |
| 52 Week Low | US$0.56 |
| Beta | 0.25 |
| 11 Month Change | -72.25% |
| 3 Month Change | -85.35% |
| 1 Year Change | -99.37% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| TCBP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -31.6% | -6.5% | -1.0% |
| 1Y | -99.4% | 14.6% | 30.3% |
Return vs Industry: TCBP underperformed the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: TCBP underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| TCBP volatility | |
|---|---|
| TCBP Average Weekly Movement | 29.1% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: TCBP's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TCBP's weekly volatility (29%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 41 | Bryan Kobel | tcbiopharm.com |
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
TC Biopharm (Holdings) Plc Fundamentals Summary
| TCBP fundamental statistics | |
|---|---|
| Market cap | US$326.27k |
| Earnings (TTM) | -US$10.87m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs TCBP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TCBP income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£8.59m |
| Earnings | -UK£8.59m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -15.68 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did TCBP perform over the long term?
See historical performance and comparison